Catalyst
Slingshot members are tracking this event:
PDUFA date for Regeneron's (REGN) Praluent (alirocumab) (ODYSSEY OUTCOMES study) for Cardiovascular events due April 28, 2019.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 26, 2019
Occurred Source:
https://investor.regeneron.com/news-releases/news-release-details/fda-approves-praluentr-alirocumab-prevent-heart-attack-stroke
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Praluent, Alirocumab, Odyssey, Cardiovascular Events
